Moins N[au] - Search Results

Year	Number of Results
1972	1
1975	1
1977	1
1979	1
1980	2
1981	1
1982	3
1983	3
1985	1
1986	3
1987	1
1988	1
1989	1
1991	1
1993	1
1995	1
1996	1
1997	2
1998	1
1999	2
2000	2
2001	2
2002	2
2004	2
2005	4
2007	1
2008	6
2009	5
2010	3
2011	2
2012	1
2013	3
2014	2
2016	1
2017	1
2024	0

1

Internal dosimetry through GATE simulations of preclinical radiotherapy using a melanin-targeting ligand.

Perrot Y, Degoul F, Auzeloux P, Bonnet M, Cachin F, Chezal JM, Donnarieix D, Labarre P, Moins N, Papon J, Rbah-Vidal L, Vidal A, Miot-Noirault E, Maigne L. Perrot Y, et al. Among authors: moins n. Phys Med Biol. 2014 May 7;59(9):2183-98. doi: 10.1088/0031-9155/59/9/2183. Epub 2014 Apr 8. Phys Med Biol. 2014. PMID: 24710744

2

123I-N-(2-diethylaminoethyl)-2-iodobenzamide: a potential imaging agent for cutaneous melanoma staging.

Moins N, D'Incan M, Bonafous J, Bacin F, Labarre P, Moreau MF, Mestas D, Noirault E, Chossat F, Berthommier E, Papon J, Bayle M, Souteyrand P, Madelmont JC, Veyre A. Moins N, et al. Eur J Nucl Med Mol Imaging. 2002 Nov;29(11):1478-84. doi: 10.1007/s00259-002-0971-6. Epub 2002 Sep 11. Eur J Nucl Med Mol Imaging. 2002. PMID: 12397467 Clinical Trial.

3

Uptake and release of two new Tc-99m labeled myocardial blood flow imaging agents in cultured cardiac cells.

Maublant JC, Moins N, Gachon P. Maublant JC, et al. Among authors: moins n. Eur J Nucl Med. 1989;15(4):180-2. doi: 10.1007/BF00253790. Eur J Nucl Med. 1989. PMID: 2753050

4

Evaluation of two (125)I-radiolabeled acridine derivatives for Auger-electron radionuclide therapy of melanoma.

Gardette M, Viallard C, Paillas S, Guerquin-Kern JL, Papon J, Moins N, Labarre P, Desbois N, Wong-Wah-Chung P, Palle S, Wu TD, Pouget JP, Miot-Noirault E, Chezal JM, Degoul F. Gardette M, et al. Among authors: moins n. Invest New Drugs. 2014 Aug;32(4):587-97. doi: 10.1007/s10637-014-0086-5. Epub 2014 Apr 2. Invest New Drugs. 2014. PMID: 24691673

5

Evaluation of radiolabeled (hetero)aromatic analogues of N-(2-diethylaminoethyl)-4-iodobenzamide for imaging and targeted radionuclide therapy of melanoma.

Chezal JM, Papon J, Labarre P, Lartigue C, Galmier MJ, Decombat C, Chavignon O, Maublant J, Teulade JC, Madelmont JC, Moins N. Chezal JM, et al. Among authors: moins n. J Med Chem. 2008 Jun 12;51(11):3133-44. doi: 10.1021/jm701424g. Epub 2008 May 16. J Med Chem. 2008. PMID: 18481842

6

Anti-melanoma efficacy of internal radionuclide therapy in relation to melanin target distribution.

Bonnet M, Mishellany F, Papon J, Cayre A, Penault-Llorca F, Madelmont JC, Miot-Noirault E, Chezal JM, Moins N. Bonnet M, et al. Among authors: moins n. Pigment Cell Melanoma Res. 2010 Oct;23(5):e1-11. doi: 10.1111/j.1755-148X.2010.00716.x. Epub 2010 Apr 22. Pigment Cell Melanoma Res. 2010. PMID: 20444199

7

B16 melanoma secretomes and in vitro invasiveness: syntenin as an invasion modulator.

Rondepierre F, Bouchon B, Bonnet M, Moins N, Chezal JM, D'Incan M, Degoul F. Rondepierre F, et al. Among authors: moins n. Melanoma Res. 2010 Apr;20(2):77-84. doi: 10.1097/CMR.0b013e32833279f2. Melanoma Res. 2010. PMID: 20016392

8

In vivo efficacy of melanoma internal radionuclide therapy with a 131I-labelled melanin-targeting heteroarylcarboxamide molecule.

Degoul F, Borel M, Jacquemot N, Besse S, Communal Y, Mishellany F, Papon J, Penault-Llorca F, Donnarieix D, Doly M, Maigne L, Miot-Noirault E, Cayre A, Cluzel J, Moins N, Chezal JM, Bonnet M. Degoul F, et al. Among authors: moins n. Int J Cancer. 2013 Sep 1;133(5):1042-53. doi: 10.1002/ijc.28103. Epub 2013 Mar 18. Int J Cancer. 2013. PMID: 23404099 Free article.

9

Proteomic studies of B16 lines: involvement of annexin A1 in melanoma dissemination.

Rondepierre F, Bouchon B, Papon J, Bonnet-Duquennoy M, Kintossou R, Moins N, Maublant J, Madelmont JC, D'Incan M, Degoul F. Rondepierre F, et al. Among authors: moins n. Biochim Biophys Acta. 2009 Jan;1794(1):61-9. doi: 10.1016/j.bbapap.2008.09.014. Epub 2008 Oct 8. Biochim Biophys Acta. 2009. PMID: 18952200

10

Melanoma affinity in mice and immunosuppressed sheep of [(125)I]N-(4-dipropylaminobutyl)-4-iodobenzamide, a new targeting agent.

Labarre P, Papon J, Rose AH, Guerquin-Kern JL, Morandeau L, Wu TD, Moreau MF, Bayle M, Chezal JM, Croisy A, Madelmont JC, Turner H, Moins N. Labarre P, et al. Among authors: moins n. Nucl Med Biol. 2008 Oct;35(7):783-91. doi: 10.1016/j.nucmedbio.2008.07.003. Nucl Med Biol. 2008. PMID: 18848663

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Results by year

Text availability

Article attribute

Article type

Publication date

63 results

Results by year

Search Page

Filters

My NCBI Filters

Results by year

Text availability

Article attribute

Article type

Publication date

Search Results

63 results

Results by year